Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.

De Falco V, Natalicchio MI, Napolitano S, Coppola N, Conzo G, Martinelli E, Zanaletti N, Vitale P, Giunta EF, Vietri MT, Vitiello PP, Ciardiello D, Marinaccio A, De Vita F, Ciardiello F, Troiani T.

Medicine (Baltimore). 2019 May;98(21):e15759. doi: 10.1097/MD.0000000000015759.

2.

TRPV2 Calcium Channel Gene Expression and Outcomes in Gastric Cancer Patients: A Clinically Relevant Association.

Zoppoli P, Calice G, Laurino S, Ruggieri V, La Rocca F, La Torre G, Ciuffi M, Amendola E, De Vita F, Petrillo A, Napolitano G, Falco G, Russi S.

J Clin Med. 2019 May 11;8(5). pii: E662. doi: 10.3390/jcm8050662.

3.

Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients.

Petrillo A, Laterza MM, Tirino G, Pompella L, Pappalardo A, Ventriglia J, Savastano B, Auricchio A, Orditura M, Ciardiello F, Galizia G, De Vita F.

J Gastrointest Oncol. 2019 Apr;10(2):314-323. doi: 10.21037/jgo.2018.12.06.

4.

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC.

Ciaramella V, Sasso FC, Di Liello R, Corte CMD, Barra G, Viscardi G, Esposito G, Sparano F, Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F.

J Exp Clin Cancer Res. 2019 Apr 26;38(1):178. doi: 10.1186/s13046-019-1176-1.

5.

The Italian Rare Pancreatic Exocrine Cancer Initiative.

Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D, Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliante F, Brandi G, Scarpa A, Cascinu S, Silvestris N.

Tumori. 2019 Apr 9:300891619839461. doi: 10.1177/0300891619839461. [Epub ahead of print]

PMID:
30967031
6.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F.

BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

7.

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions.

Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F.

Cancers (Basel). 2019 Mar 21;11(3). pii: E399. doi: 10.3390/cancers11030399. Review.

8.

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.

Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E.

J Exp Clin Cancer Res. 2019 Jan 28;38(1):41. doi: 10.1186/s13046-019-1035-0.

9.

PARP inhibitors in ovarian cancer.

Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, De Vita F, Pignata S, Ciardiello F, Orditura M.

Cancer Treat Rev. 2019 Feb;73:1-9. doi: 10.1016/j.ctrv.2018.12.002. Epub 2018 Dec 4. Review.

10.

The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In Vivo.

De Marco C, Rinaldo N, De Vita F, Forzati F, Caira E, Iovane V, Paciello O, Montanaro D, D'Andrea S, Baldassarre G, Papparella S, Malanga D, Baldi A, Viglietto G.

Mol Cancer Ther. 2019 Feb;18(2):482-493. doi: 10.1158/1535-7163.MCT-18-0134. Epub 2018 Nov 13.

PMID:
30425132
11.

What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.

Tirino G, Pompella L, Petrillo A, Laterza MM, Pappalardo A, Caterino M, Orditura M, Ciardiello F, Galizia G, De Vita F.

Int J Mol Sci. 2018 Sep 7;19(9). pii: E2659. doi: 10.3390/ijms19092659. Review.

12.

Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram.

Pietrantonio F, Barretta F, Fanotto V, Park SH, Morano F, Fucà G, Niger M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G.

Oncology. 2018;95(6):344-352. doi: 10.1159/000491753. Epub 2018 Aug 21.

PMID:
30130791
13.

Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.

Diana A, Franzese E, Centonze S, Carlino F, Della Corte CM, Ventriglia J, Petrillo A, De Vita F, Alfano R, Ciardiello F, Orditura M.

Curr Oncol Rep. 2018 Aug 20;20(10):76. doi: 10.1007/s11912-018-0726-6. Review.

PMID:
30128845
14.

Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.

Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo F.

Breast. 2018 Oct;41:165-171. doi: 10.1016/j.breast.2018.08.002. Epub 2018 Aug 4.

PMID:
30103105
15.

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.

Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F.

Gastroenterol Res Pract. 2018 Jun 10;2018:2373868. doi: 10.1155/2018/2373868. eCollection 2018.

16.

Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy.

Petrillo A, Laterza MM, Tirino G, Pompella L, Ventriglia J, Pappalardo A, Famiglietti V, Martinelli E, Ciardiello F, Orditura M, Galizia G, De Vita F.

Future Oncol. 2018 Oct;14(24):2493-2505. doi: 10.2217/fon-2018-0167. Epub 2018 Jul 3.

PMID:
29969285
17.

Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis.

Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D, Reni M, Cascinu S, Silvestris N.

Pancreas. 2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063.

PMID:
29771769
18.

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F.

Target Oncol. 2018 Apr;13(2):227-234. doi: 10.1007/s11523-018-0562-5.

PMID:
29582224
19.

Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.

Tehfe M, Tabchi S, Laterza MM, De Vita F.

Future Oncol. 2018 Feb;14(3):223-228. doi: 10.2217/fon-2017-0434. Epub 2018 Jan 10.

PMID:
29318901
20.

Plantar Kaposi Sarcoma Revealed by Antisynthetase Syndrome.

Sellitto A, Adinolfi LE, Romano C, Iovino F, Auriemma PP, Russo D, de Vita F.

J Clin Rheumatol. 2018 Aug;24(5):281-285. doi: 10.1097/RHU.0000000000000650. No abstract available.

PMID:
29239932
21.

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment.

Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, Napolitano S, Rachiglio AM, Normanno N, Cappabianca S, Reginelli A, Bisceglie MD, Latiano TP, Maiello E, Orditura M, De Vita F, Morgillo F, Ciardiello F, Troiani T.

ESMO Open. 2017 Jul 29;2(3):e000177. doi: 10.1136/esmoopen-2017-000177. eCollection 2017.

22.

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M.

Clin Cancer Res. 2018 Mar 1;24(5):1082-1089. doi: 10.1158/1078-0432.CCR-17-2781. Epub 2017 Dec 5.

23.

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.

Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, de Vita F, Ciardiello F, Orditura M.

Oncotarget. 2017 Aug 22;8(44):76479-76491. doi: 10.18632/oncotarget.20385. eCollection 2017 Sep 29.

24.

Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.

Laterza MM, Pompella L, Petrillo A, Tirino G, Pappalardo A, Orditura M, Troiani T, Ciardiello F, Di Martino N, De Vita F.

Med Oncol. 2017 Oct 17;34(11):186. doi: 10.1007/s12032-017-1046-7.

PMID:
29043514
25.

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D.

Lancet Oncol. 2017 Nov;18(11):1467-1482. doi: 10.1016/S1470-2045(17)30566-1. Epub 2017 Sep 25.

26.

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.

Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F.

ESMO Open. 2017 Feb 20;1(6):e000086. doi: 10.1136/esmoopen-2016-000086. eCollection 2016.

27.

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.

Rossetti S, D'Aniello C, Iovane G, Scagliarini S, Laterza MM, De Vita F, Savastano C, Cartenì G, Porricelli MA, Berretta M, Pisconti S, Facchini G, Cavaliere C.

Front Pharmacol. 2017 Jul 20;8:484. doi: 10.3389/fphar.2017.00484. eCollection 2017.

28.

Thyroid Surgery: To Drain or Not to Drain, That Is the Problem - A Randomized Clinical Trial.

Schietroma M, Pessia B, Bianchi Z, De Vita F, Carlei F, Guadagni S, Amicucci G, Clementi M.

ORL J Otorhinolaryngol Relat Spec. 2017;79(4):202-211. doi: 10.1159/000464137. Epub 2017 Jul 15.

PMID:
28715809
29.

Mitochondrial AKAP1 supports mTOR pathway and tumor growth.

Rinaldi L, Sepe M, Delle Donne R, Conte K, Arcella A, Borzacchiello D, Amente S, De Vita F, Porpora M, Garbi C, Oliva MA, Procaccini C, Faicchia D, Matarese G, Zito Marino F, Rocco G, Pignatiello S, Franco R, Insabato L, Majello B, Feliciello A.

Cell Death Dis. 2017 Jun 1;8(6):e2842. doi: 10.1038/cddis.2017.241.

30.

[Gastric carcinoma: an evolutionary scenario.]

Gelsomino F, Spallanzani A, De Vita F, Di Bartolomeo M, Gavazzi C, Rimassa L, Cascinu S.

Recenti Prog Med. 2017 Mar;108(3):120-127. doi: 10.1701/2656.27234. Review. Italian.

PMID:
28398405
31.

Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience.

Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Diana A, Castellano P, De Vita F, Orditura M.

PLoS One. 2017 Apr 5;12(4):e0173619. doi: 10.1371/journal.pone.0173619. eCollection 2017.

32.

Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report.

Fasano M, Fabozzi A, Giordano G, Venturini F, Aurilio G, Cantile F, Fabozzi T, Ricci V, Santabarbara G, Morgillo F, Ciardiello F, De Vita F.

Oncol Lett. 2017 Feb;13(2):979-983. doi: 10.3892/ol.2016.5523. Epub 2016 Dec 20.

33.

Predictive biomarkers along gastric cancer pathogenetic pathways.

Panarese I, De Vita F, Ronchi A, Romano M, Alfano R, Di Martino N, Zito Marino F, Ferraraccio F, Franco R.

Expert Rev Anticancer Ther. 2017 May;17(5):417-425. doi: 10.1080/14737140.2017.1301207. Epub 2017 Mar 15. Review.

PMID:
28277834
34.

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.

Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F.

Oncol Lett. 2016 Dec;12(6):4505-4509. doi: 10.3892/ol.2016.5279. Epub 2016 Oct 18.

35.

Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis.

Orditura M, Galizia G, Diana A, Saccone C, Cobellis L, Ventriglia J, Iovino F, Romano C, Morgillo F, Mosca L, Diadema MR, Lieto E, Procaccini E, De Vita F, Ciardiello F.

ESMO Open. 2016 Mar 7;1(2):e000038. eCollection 2016.

36.

Pancreatic stump closure after pancreatoduodenectomy in elderly patients: a retrospective clinical study.

Mauriello C, Polistena A, Gambardella C, Tartaglia E, Orditura M, De Vita F, Santini L, Avenia N, Conzo G.

Aging Clin Exp Res. 2017 Feb;29(Suppl 1):35-40. doi: 10.1007/s40520-016-0657-8. Epub 2016 Nov 11.

37.

Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.

D'Aniello C, Vitale MG, Farnesi A, Calvetti L, Laterza MM, Cavaliere C, Della Pepa C, Conteduca V, Crispo A, De Vita F, Grillone F, Ricevuto E, De Tursi M, De Vivo R, Di Napoli M, Cecere SC, Iovane G, Amore A, Piscitelli R, Quarto G, Pisconti S, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Naglieri E, Galli L, Cartenì G, De Giorgi U, Pignata S, Facchini G, Rossetti S.

Front Pharmacol. 2016 Sep 28;7:331. eCollection 2016.

38.

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.

De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M.

BMC Cancer. 2016 Sep 2;16(1):709. doi: 10.1186/s12885-016-2671-9.

39.

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M.

Int J Cancer. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. Epub 2016 Sep 16.

40.

Quality of wound dressings: a first step in establishing shared criteria and objective procedures to evaluate their performance.

Mennini N, Greco A, Bellingeri A, De Vita F, Petrella F.

J Wound Care. 2016 Aug;25(8):428-37. doi: 10.12968/jowc.2016.25.8.428.

PMID:
27523654
41.

Instrumental and Non-Instrumental Evaluation of 4-Meter Walking Speed in Older Individuals.

Maggio M, Ceda GP, Ticinesi A, De Vita F, Gelmini G, Costantino C, Meschi T, Kressig RW, Cesari M, Fabi M, Lauretani F.

PLoS One. 2016 Apr 14;11(4):e0153583. doi: 10.1371/journal.pone.0153583. eCollection 2016.

42.

Malignant transformation in non-recurrent peritoneal cystic mesothelioma Our experience and review of the literature.

Santangelo G, Accardo M, De Vita F, Del Giudice S, Gallucci F, Fabozzi A, De Falco M.

Ann Ital Chir. 2016 Jan 29;87(ePub). pii: S2239253X16023343.

PMID:
27031307
43.

Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.

Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, Nappi A, Bordonaro AR, Rachiglio M, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E; CAPRI-GOIM Investigators; CAPRI-GOIM investigators.

Ann Oncol. 2016 Jun;27(6):1055-61. doi: 10.1093/annonc/mdw136. Epub 2016 Mar 21.

PMID:
27002107
44.

The Role of the Multiple Hormonal Dysregulation in the Onset of "Anemia of Aging": Focus on Testosterone, IGF-1, and Thyroid Hormones.

Maggio M, De Vita F, Fisichella A, Lauretani F, Ticinesi A, Ceresini G, Cappola A, Ferrucci L, Ceda GP.

Int J Endocrinol. 2015;2015:292574. doi: 10.1155/2015/292574. Epub 2015 Dec 8. Review.

45.

Pancreatic neuroendocrine tumors: Nosography, management and treatment.

Orditura M, Petrillo A, Ventriglia J, Diana A, Laterza MM, Fabozzi A, Savastano B, Franzese E, Conzo G, Santini L, Ciardiello F, De Vita F.

Int J Surg. 2016 Apr;28 Suppl 1:S156-62. doi: 10.1016/j.ijsu.2015.12.052. Epub 2015 Dec 18. Review.

46.

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F.

Oncotarget. 2016 Jan 26;7(4):4265-78. doi: 10.18632/oncotarget.6559.

47.

Relationship between Carotenoids, Retinol, and Estradiol Levels in Older Women.

Maggio M, de Vita F, Lauretani F, Bandinelli S, Semba RD, Bartali B, Cherubini A, Cappola AR, Ceda GP, Ferrucci L.

Nutrients. 2015 Aug 5;7(8):6506-19. doi: 10.3390/nu7085296.

48.

INSULIN-LIKE GROWTH FACTOR-1 AND ANEMIA IN OLDER SUBJECTS: THE INCHIANTI STUDY.

De Vita F, Maggio M, Lauretani F, Crucitti L, Bandinelli S, Mammarella F, Landi F, Ferrucci L, Ceda GP.

Endocr Pract. 2015 Nov;21(11):1211-8. doi: 10.4158/EP14100.OR. Epub 2015 Jul 27.

49.

Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review.

Mauriello C, Napolitano S, Gambardella C, Candela G, De Vita F, Orditura M, Sciascia V, Tartaglia E, Lanza M, Santini L, Conzo G.

Int J Surg. 2015 Sep;21 Suppl 1:S10-4. doi: 10.1016/j.ijsu.2015.04.089. Epub 2015 Jun 26. Review.

50.

Pancreatic fistula following pancreatoduodenectomy. Evaluation of different surgical approaches in the management of pancreatic stump. Literature review.

Conzo G, Gambardella C, Tartaglia E, Sciascia V, Mauriello C, Napolitano S, Orditura M, De Vita F, Santini L.

Int J Surg. 2015 Sep;21 Suppl 1:S4-9. doi: 10.1016/j.ijsu.2015.04.088. Epub 2015 Jun 26. Review.

Supplemental Content

Loading ...
Support Center